FI3687562T3 - Toistuvan idiopaattisen perikardiitin hoito antamalla interleukin-1-reseptoriantagonistifuusioproteiinia - Google Patents
Toistuvan idiopaattisen perikardiitin hoito antamalla interleukin-1-reseptoriantagonistifuusioproteiinia Download PDFInfo
- Publication number
- FI3687562T3 FI3687562T3 FIEP18786587.8T FI18786587T FI3687562T3 FI 3687562 T3 FI3687562 T3 FI 3687562T3 FI 18786587 T FI18786587 T FI 18786587T FI 3687562 T3 FI3687562 T3 FI 3687562T3
- Authority
- FI
- Finland
- Prior art keywords
- rilonacept
- pericarditis
- use according
- treatment
- recurrent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563387P | 2017-09-26 | 2017-09-26 | |
| US201862616819P | 2018-01-12 | 2018-01-12 | |
| US201862625075P | 2018-02-01 | 2018-02-01 | |
| US201862639425P | 2018-03-06 | 2018-03-06 | |
| US201862654291P | 2018-04-06 | 2018-04-06 | |
| US201862691552P | 2018-06-28 | 2018-06-28 | |
| US201862716331P | 2018-08-08 | 2018-08-08 | |
| PCT/US2018/052985 WO2019067639A1 (en) | 2017-09-26 | 2018-09-26 | TREATMENT OF INFLAMMATORY CONDITIONS BY ADMINISTRATION OF INTERLEUKIN-1 RECEPTOR ANTAGONIST FUSION PROTEIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3687562T3 true FI3687562T3 (fi) | 2025-04-25 |
Family
ID=63858163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18786587.8T FI3687562T3 (fi) | 2017-09-26 | 2018-09-26 | Toistuvan idiopaattisen perikardiitin hoito antamalla interleukin-1-reseptoriantagonistifuusioproteiinia |
Country Status (12)
| Country | Link |
|---|---|
| US (8) | US11026997B2 (https=) |
| EP (2) | EP3687562B1 (https=) |
| JP (3) | JP7301815B2 (https=) |
| CA (1) | CA3075538A1 (https=) |
| DK (1) | DK3687562T3 (https=) |
| ES (1) | ES3023044T3 (https=) |
| FI (1) | FI3687562T3 (https=) |
| HU (1) | HUE071206T2 (https=) |
| PL (1) | PL3687562T3 (https=) |
| PT (1) | PT3687562T (https=) |
| SI (1) | SI3687562T1 (https=) |
| WO (1) | WO2019067639A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3075538A1 (en) | 2017-09-26 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein |
| WO2026003765A1 (en) | 2024-06-25 | 2026-01-02 | Kiniksa Pharmaceuticals, Gmbh | Formulations of anti-interleukin 1 receptor 1 antibodies |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060171948A1 (en) * | 2005-02-02 | 2006-08-03 | Weinstein Steven P | Methods of using IL-1 antagonists to reduce C-reactive protein |
| WO2012078101A1 (en) | 2010-12-07 | 2012-06-14 | Swedish Orphan Biovitrum Ab (Publ) | Method for the treatment of il-1 mediated diseases |
| WO2014035361A1 (en) | 2012-08-26 | 2014-03-06 | R-PHARM, CJSC (Closed Joint Stock Company) | IL-1β INHIBITOR COMPOSITION AND USE THEREOF |
| JP6225197B2 (ja) | 2013-02-15 | 2017-11-01 | アール−ファーム・ジョイント・ストック・カンパニーＲ−Ｐｈａｒｍ，Ｊｓｃ | ＩＬ−１β阻害剤組成物およびその使用 |
| WO2015147789A1 (en) | 2014-03-24 | 2015-10-01 | R-Pharm Overseas, Inc. | Human il 1-r1 derived inhibitor of il-1b |
| CA3075538A1 (en) | 2017-09-26 | 2019-04-04 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein |
-
2018
- 2018-09-26 CA CA3075538A patent/CA3075538A1/en active Pending
- 2018-09-26 FI FIEP18786587.8T patent/FI3687562T3/fi active
- 2018-09-26 PL PL18786587.8T patent/PL3687562T3/pl unknown
- 2018-09-26 WO PCT/US2018/052985 patent/WO2019067639A1/en not_active Ceased
- 2018-09-26 PT PT187865878T patent/PT3687562T/pt unknown
- 2018-09-26 HU HUE18786587A patent/HUE071206T2/hu unknown
- 2018-09-26 DK DK18786587.8T patent/DK3687562T3/da active
- 2018-09-26 US US16/143,391 patent/US11026997B2/en active Active
- 2018-09-26 ES ES18786587T patent/ES3023044T3/es active Active
- 2018-09-26 SI SI201831227T patent/SI3687562T1/sl unknown
- 2018-09-26 EP EP18786587.8A patent/EP3687562B1/en active Active
- 2018-09-26 JP JP2020516827A patent/JP7301815B2/ja active Active
- 2018-09-26 EP EP25150543.4A patent/EP4541367A3/en active Pending
-
2021
- 2021-03-22 US US17/208,409 patent/US20210283224A1/en not_active Abandoned
- 2021-11-16 US US17/527,956 patent/US11464830B2/en active Active
-
2022
- 2022-09-02 US US17/929,458 patent/US11944666B2/en active Active
- 2022-09-02 US US17/929,572 patent/US20220409699A1/en not_active Abandoned
-
2023
- 2023-03-14 JP JP2023039474A patent/JP7564270B2/ja active Active
- 2023-05-05 US US18/313,134 patent/US11844765B2/en active Active
-
2024
- 2024-05-22 US US18/671,801 patent/US12201673B2/en active Active
- 2024-07-09 JP JP2024110108A patent/JP2024133112A/ja active Pending
-
2025
- 2025-07-23 US US19/278,317 patent/US20250345396A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220072102A1 (en) | 2022-03-10 |
| EP3687562A1 (en) | 2020-08-05 |
| EP3687562B1 (en) | 2025-03-19 |
| US20240293510A1 (en) | 2024-09-05 |
| DK3687562T3 (da) | 2025-04-14 |
| JP7564270B2 (ja) | 2024-10-08 |
| JP7301815B2 (ja) | 2023-07-03 |
| US20210283224A1 (en) | 2021-09-16 |
| ES3023044T3 (en) | 2025-05-29 |
| EP4541367A3 (en) | 2025-07-30 |
| US11464830B2 (en) | 2022-10-11 |
| SI3687562T1 (sl) | 2025-06-30 |
| US20220409699A1 (en) | 2022-12-29 |
| US12201673B2 (en) | 2025-01-21 |
| WO2019067639A1 (en) | 2019-04-04 |
| JP2024133112A (ja) | 2024-10-01 |
| PT3687562T (pt) | 2025-04-03 |
| EP4541367A2 (en) | 2025-04-23 |
| HUE071206T2 (hu) | 2025-08-28 |
| US20250345396A1 (en) | 2025-11-13 |
| US20230012740A1 (en) | 2023-01-19 |
| US20230346887A1 (en) | 2023-11-02 |
| US20190151417A1 (en) | 2019-05-23 |
| JP2020535140A (ja) | 2020-12-03 |
| CA3075538A1 (en) | 2019-04-04 |
| US11026997B2 (en) | 2021-06-08 |
| US11844765B2 (en) | 2023-12-19 |
| JP2023063426A (ja) | 2023-05-09 |
| US11944666B2 (en) | 2024-04-02 |
| PL3687562T3 (pl) | 2025-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Sleep, testosterone and cortisol balance, and ageing men | |
| FI3902547T3 (fi) | Csf1r-inhibiittoreita käytettäväksi syövän hoitamisessa | |
| Ghosal et al. | Glucocorticoid receptors in the nucleus of the solitary tract (NTS) decrease endocrine and behavioral stress responses | |
| MX2015005699A (es) | Una composicion para tratar diabetes o diabesidad que comprende un analogo de oxintomodulina. | |
| SI2625199T1 (en) | Procedures for treating psoriasis using IL-17 antagonists | |
| RU2016104398A (ru) | Использование антагониста vegf для лечения ретролентальной фиброплазии | |
| MX2018004309A (es) | Terapias combinadas para tratar el cancer. | |
| Steiner et al. | Examining the role of endogenous orexins in hypothalamus–pituitary–adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat | |
| BR112022000382A2 (pt) | Administração de agonista de sting e inibidores de checkpoint | |
| Schenk et al. | Profile of MDMA self-administration from a large cohort of rats: MDMA develops a profile of dependence with extended testing | |
| FI3687562T3 (fi) | Toistuvan idiopaattisen perikardiitin hoito antamalla interleukin-1-reseptoriantagonistifuusioproteiinia | |
| Loveridge et al. | Systemic non-opioid adjuvant analgesics: their role in acute postoperative pain in adults | |
| RU2013150024A (ru) | Способы контроля и лечения хронической боли с применением hcg | |
| Kurganova et al. | A role of melatonin in the treatment of low back pain | |
| Drummond et al. | Increased bilateral expression of α1-adrenoceptors on peripheral nerves, blood vessels and keratinocytes does not account for pain or neuroinflammatory changes after distal tibia fracture in rats | |
| RU2016124538A (ru) | Антагонисты гастрина для лечения и профилактики остеопороза | |
| Chen et al. | Celecoxib alleviates oxaliplatin-induced hyperalgesia through inhibition of spinal ERK1/2 signaling | |
| Sekulić et al. | Short term treatment with lithium carbonate as adjunct to radioiodine treatment for long-lasting Graves’ hyperthyroidism | |
| Aggarwal et al. | Premature ejaculation–dose and duration dependent effect of fluoxetine: a histological study on seminal vesicle of albino rats | |
| Rad | Autoimmune progesterone dermatitis: case report | |
| Strand et al. | P213 High baseline serum IL-6 predicts increased sarilumab treatment response for patient reported symptoms and health-related quality of life among RA patients with inadequate response to MTX | |
| NZ773583A (en) | Methods of treating psoriasis | |
| Smyk | APPLICATION OF BODY-ORIENTED PSYCHO-CORRECTION IN THE BRONCHIAL ASTHMA COMPLEX THERAPY | |
| Montoro De Francisco | Local pustulosis: case report | |
| NZ773583B2 (en) | Methods of treating psoriasis |